Please visit answersincme.com/860/101707775-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. [Presented by Erika Hamilton, MD, FASCO; Komal Jhaveri, MD, FACP, FASCO; and John Allen Piede, MD. In this activity, experts in breast cancer provide a practical, community-focused discussion on integrating ESR1 mutation testing, applying emerging data on novel endocrine therapies, such as SERDs, and personalizing treatment strategies for patients with HR+, HER2− advanced breast cancer. Upon completion of this activity, participants should be better able to: Integrate testing for ESR1 mutations at appropriate times into practice workflows in the treatment of patients with HR-positive, HER2-negative advanced breast cancer; Evaluate the clinical implications of the latest evidence for approved and late-stage emerging novel oral SERDs in patients with HR-positive, HER2-negative advanced breast cancer; and Apply multidisciplinary, patient-centered strategies for optimizing treatment outcomes with novel oral SERDs in patients with HR-positive, HER2-negative advanced breast cancer.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related